Cara Therapeutics Inc (NASDAQ: CARA) stock closed at $5.99 on 1/24/25 after a major increase of 18.4%. However, trading volume in this advance was unusually low at 63% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 34.3% during the last week.
Current PriceTarget Research Rating
Cara Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Cara Therapeutics has a very low Power Rating of 12 and a very low Appreciation Score of 4, leading to the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment